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Abstract
Background CD8+ regulatory T cells (Treg) have been
considered to be involved in a model of ocular-induced
tolerance, known as anterior chamber-associated immune
deviation (ACAID). The mechanisms of suppression by
CD8+ T cells in ACAID remain only poorly understood.
TGF-β1 is considered as an inhibitory cytokine for
immunosuppression in some models. The production of
TGF-β1 by CD8+ T cells in ACAID, and whether CD8+ T
cells exert suppression through TGF-β1, is unknown.
Methods The suppressive effect of CD8+ T cells in ACAID
mice was determined by a local adoptive transfer (LAT)
assay. The production of TGF-β1 by CD8+ T cells was
measured by enzyme-linked immunosorbent assay
(ELISA). Anti-TGF-β1 antibodies were used in the LAT
assay to test if they could block the inhibitory effect of
CD8+ T cells.
Results CD8+ T cells from ACAID mice were shown to
block the delayed-type hypersensitivity (DTH) response in
an antigen-specific manner in a LAT assay. These CD8+ T
cells secreted TGF-β1, and their suppression could partially
be blocked by anti-TGF-β1 antibodies.
Conclusions Our study confirms that CD8+ T cells from
ACAID mice possess inhibitory properties. This population
exerts part of its suppressive function via the production of
TGF-β1.
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Introduction
An injection of soluble protein antigen (Ag) into the
anterior chamber (AC) of the eye induces a kind of immune
tolerance termed anterior chamber-associated immune
deviation (ACAID), which is characterized by impairment
of the delayed-type hypersensitivity (DTH) response. There
are two distinct populations of regulatory T cells (Tregs)
involved in the suppression of DTH responses in ACAID.
The efferent regulatory cells involved in the impaired
expression of DTH are considered to be antigen-specific
CD8+ T cells [1].
Transforming growth factor-β (TGF-β) is a regulatory
cytokine with a pivotal role in regulating immune responses
[2]. There are three homologous TGF-β isoforms in
mammals, TGF-β1, 2, and 3, encoded by different genes.
TGF-β1 is the predominant isoform expressed by the
immune system, although all three isoforms have similar
properties in vitro [3]. Recent studies have suggested that
TGF-β1 produced by CD4+ Tregs may serve as an effective
mechanism of suppression of these cells, possibly via
Graefes Arch Clin Exp Ophthalmol (2009) 247:87–92
DOI 10.1007/s00417-008-0947-8
Liqiong Jiang and Hao He contributed equally to this work.
L. Jiang :H. He :X. Lin :H. Zhou :X. Huang
State Key Laboratory of Ophthalmology,
Zhongshan Ophthalmic Center,
Guangzhou, People’s Republic of China
P. Yang (*)
The First Affiliated Hospital, Chongqing Medical University,
Youyi Road 1,
Chongqing 400016, People’s Republic of China
e-mail: peizengy@126.com
A. Kijlstra
Department of Ophthalmology, Eye Research Institute Maastricht,
University Hospital Maastricht,
Maastricht, The Netherlands
A. Kijlstra
Animal Sciences Group, Wageningen University,
Lelystad, The Netherlands
binding to Treg cell TGF-β receptors [4]. Moreover, it
plays an essential role in the maintenance of Foxp3
expression in CD4+ CD25+ Tregs in the periphery [5].
The production of TGF-β1 by CD8+ T cells and the exact
role of this cytokine derived from splenic CD8+ T cells
during ACAID is unknown and was, therefore, the subject
of our study. Here we show that splenic CD8+ T cells from
ACAID mice produce a large amount of TGF-β1, and that
this cytokine is involved in the suppression exerted by
CD8+ T cells during ACAID.
Materials and methods
Mice
Female 6–8 week old C57BL/6 (B6; H-2b) mice were
purchased from the animal facility at Sun Yat-sen University,
Peoples Republic of China. All mice were treated according
to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
Treatment of mice
ACAID was induced as described previously using micro-
injection of ovalbumin (OVA; Sigma, St. Louis, MO, USA)
into the AC of the eye [6]. Primed mice received a
subcutaneous (s.c.) injection of 250 μg of OVA or BSA
(Sigma-Aldrich, Steinheim, Germany) emulsified 1:1 in
Complete Freund’s adjuvant (CFA, Sigma-Aldrich, Steinheim,
Germany) in a total volume of 200 μl. The numbers of mice
used in the various experiments are mentioned in the figure
legends.
DTH assay
The ear-swelling response was measured to indicate the
DTH response to OVA or BSA as described previously [7].
Briefly, 7 days after subcutaneous immunization, mice
were challenged respectively by intradermal injection
of Ag (200 μg of OVA/10 μl of PBS) and an equal
volume of sterile PBS into the right and left ear
pinnae. Ear pinnae of experimental and control animals
were measured with a Mitutoyo engineer’s micrometer
(Mitutoyo, Japan) immediately before challenge and
24 h later.
Preparation of peritoneal exudate cells (PECs)
PECs were collected from C57BL/6 mice following
intraperitoneal injection with thioglycolate (Sigma-Aldrich)
as described previously [8]. More than 90% of the adherent
cells were identified as being F4/80+ cells, using flow
cytometry (FCM).
Cell isolation and culture
Purification of CD8+ T cells from the spleen of the mice
was described previously [9]. The purity of CD8+ T cells
was identified to be >95% according to FCM analysis. For
cytokine assay, purified CD8+ T cells (2×105 cells/well)
were cultured in 96-well culture plates containing isolated
PECs (2×105 cells/well) in the presence of 200 μg/ml OVA
or BSA at 37°C in complete RPMI 1640 medium for
24 hours. Cultures containing PECs (2×105 cells/well) and
OVA (200 μg/ml OVA) were used as control.
TGF-β1 and IL-10 assay
TGF-β1 and IL-10 in the collected supernatants of cell
cultures were analyzed using the R&D Duoset ELISA
development system, according to the manufacturer’s instruc-
tions. For TGF-β1, samples were activated by incubation with
1 N HCL for 10 min, and subsequently neutralized with 1.2N
NaOH/0.5 M HEPES. The background level of TGF-β1 from
PECs was determined separately, and subtracted from these
samples. The limits of TGF-β1 and IL-10 detection were
31.2 pg/ml and 15.6 pg/ml respectively.
LAT assay
A LAT assay, as described previously [10], was developed
to test suppressor cells during ACAID. Briefly, putative
suppressor cells consisted of purified CD8+ T cells
separated from splenocytes of ACAID mice. Responder
cells were collected from splenocytes of OVA or BSA
primed mice. Both suppressor cells and responder cells were
harvested on day 7 after AC-inoculation and conventional
immunization, and were suspended at 5×107 cells/ml in
10 mg/ml OVA or BSA. The immune and suppressor cells
populations were then mixed 1:1 in the presence of OVA or
BSA (10 mg/ml). Then, the cell mixture was injected
(20 μl) into the ear pinnae of naïve C57BL/6 mice. Ear
swelling was measured 24 hours later to evaluate DTH. In
order to clarify whether TGF-β1 has an effect on
suppression mediated by CD8+ T cells from ACAID mice,
additional LAT assays were performed after blocking with
mouse anti-TGF-β1 mAb (100 μg/ml) or matched isotype
(100 μg/ml) (R&D Systems, Inc., USA).
Statistical analyses
Statistical analyses were performed by one-way ANOVA using
SPSS 11.0. Values of p<0.05 were considered significant.
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Results
CD8+ T cells from ACAID mice specifically inhibit DTH
response in vivo
The LAT assay was used to study the inhibitory function of
antigen-specific efferent suppressor cells from ACAID
mice. Our results showed that the ear-swelling responses
of mice that received responder cells mixed with CD8+
cells from normal mice (positive control) displayed signif-
icant ear swelling indicative of DTH. This ear-swelling
response induced by OVA-primed responder cells was
significantly reduced when CD8+ T cells from OVA-
induced ACAID mice were co-injected with these cells.
However, OVA-specific CD8+ T cells did not inhibit the
DTH response induced by BSA primed responder cells.
The results of a typical experiment are shown in Fig. 1.
CD8+ T cells from ACAID mice secreted TGF-β1
Previous studies have indicated that TGF-β and IL-10 play
an important role as immunosuppressive cytokines in
ACAID [11]. In this study, we examined the production
of these cytokines by CD8+ T cells during ACAID. As
shown in Fig. 2, CD8+ T cells from ACAID mice pulsed
with OVA produced a higher level of TGF-β1 than those
from normal mice. However, when an irrelevant antigen,
BSA, was used, there was no difference between these two
groups concerning the production of TGF-β1. The levels of
IL-10 secreted by CD8+ T cells from both ACAID mice and
normal mice were below the detection limit of the assay.
Anti-TGF-β1 antibody partially blocked the suppression
by ACAID CD8+ T cells
As CD8+ T cells could secrete TGF-β1, a further experiment
was performed to examine whether the inhibitory effect of
these cells was mediated by TGF-β1. Neutralizing anti-TGF-
β1 antibodies or matched isotype was used in the blocking
study. The result of a representative experiment is presented
in Fig. 3. The mice receiving an injection of neutralizing
anti-TGF-β1 antibodies showed an ear-swelling response
that was approximately half of that observed in the positive
control. Isotype control did not affect the impaired ear-
swelling response.
Discussion
In this study, we showed that CD8+ T cells from ACAID
mice could specifically inhibit the expression of the DTH
response. In vitro experiments showed that these cells were
able to produce TGF-β1 in an antigen-specific manner. The
suppressive effect of CD8+ T cells from ACAID mice could
be partially blocked by anti-TGF-β1 antibodies in a LAT
assay. All these results suggest that secretion of TGF-β1
may be an important suppressive property of CD8+ T cells
in ACAID.
It has been shown that CD8+ T cells are necessary in the
development of ACAID [12]. In a previous study [9], we
showed increased frequencies of CD8+ T cells as well as
CD8+ Foxp3+ T cells in the spleens of ACAID mice. The
inhibitory property of these CD8+ T cells was shown by a
Fig. 1 Effect of CD8+ T cells from ACAID mice on expression of
DTH in vivo. Regulator cells consisted of purified CD8+ T cells
separated from splenocytes of OVA-induced ACAID mice. Responder
cells were collected from splenocytes(SPL) of OVA- or BSA-primed
mice. As a negative control, naïve spleen cells were used as responder
cells and purified CD8+ T cells from untreated mice were used as
regulatory cells. Primed spleen cells were used as responder cells and
purified CD8+ T cells from naive mice were used as regulatory cells
for a positive control. Ear swelling was measured at 24 hours. Mean ±
SD ear-swelling responses are presented (n=5). The experiments were
repeated twice with similar results. *p<0.05; NS, p>0.05
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decreased DTH response in a LAT assay. The present study
confirmed our previous observation in another group of
mice using the LAT assay. Furthermore, it extends these
previous observations focusing on TGF-β1. Our results
suggest that CD8+ T cells may function as inhibitory cells,
generally known as Tregs.
TGF-β and IL-10 have been shown to be the suppressive
cytokines in immune tolerance models including ACAID
[13–22]. TGF-β1, a major component of the TGF-β family,
along with TGF-β2 has been proven to be involved in the
immunoregulation. In general, TGF-β1 is implicated in the
regulating autoimmune and inflammatory diseases and
converting CD4+ CD25- T cells into Treg in vitro [3, 23–
25]. Whereas TGF-β2 mainly contributes to the intraocular
immunosuppressive microenvironment and endows APC
with ACAID-inducing capability [8, 12, 26], Kezuka et al.
[8] demonstrated that TGF-β2 was not required for the
suppression mediated by in vito-activated ACAID-like
CD8+ Treg. In this study we tested whether CD8+ T cells
could produce TGF-β1, a cytokine important to the Treg.
Our results showed that splenic CD8+ T cells from ACAID
mice could secrete a large amount of TGF-β1 upon
stimulation with OVA, an antigen used for induction of
ACAID. This result suggests that primed CD8+ T cells are
able to secrete TGF-β1 in an antigen-specific manner.
Blocking experiments with anti-TGF-β1 antibodies could
partially inhibit the function of CD8+ Tregs. This result is
consistent with that observed by Weiner et al. [27] in an
oral tolerance model. They found that both CD4 and CD8
regulatory cells mediated their down-regulatory effect
through secreting TGF-β. It has also been reported that
induced CD8+ Tregs from another immune tolerance model
in lupus-prone mice, in which artificial peptide is injected
intravenously, secrete abundant TGF-β1. Antibodies to
TGF-β can abrogate the suppression of these CD8+ Tregs
[28]. All these results suggest that TGF-β1 is a predomi-
nant cytokine involved in the function of CD8+ T cells from
ACAID model as well as other immune tolerance models.
It has been shown that the generation of the efferent
CD8+ Tregs in ACAID is dependent on the production of
IL-10 by NKT cells and δγ T cells [29, 30], and that IL-10
is necessary for APC to acquire the ability of inducing
ACAID [11]. However, it is unknown whether IL-10
functions as a suppressive factor in the effector phase by
CD8+ Treg. We further detected the IL-10 secretion by
splenic CD8+ T cells from ACAID mice using ELISA.
However, the level of IL-10 secreted by these cells was
below the detection limit of the assay (15.6 pg/ml). One of
the reasons may be that IL-10 is not required for CD8+
Treg-mediated suppression. Another possibility could be
that this assay is not sensitive enough to define the different
level of IL-10 secretion by CD8+ T cells between ACAID
mice and normal mice. A more sensitive technique is
expected to clarify this issue.
Our result differs from that presented by Kosiewicz et al.
[31], who showed that TGF-β1 was produced primarily by
the splenic CD4+ T and non-T cells, but not by CD8+ T
cells, during ACAID. This difference may be due to the
different culture conditions used in the experiments. CD4+
and CD8+ T cells were not separated from each other in
their study. The response of CD8+ T cells to OVA
Fig. 2 TGF-β1 production by CD8+ T cells from ACAID mice.
Purified CD8+ T cells (2×105 cells/well) from normal mice and ACAID
mice were incubated in the presence of PECs (APC, 2×105 cells/well)
and pulsed with OVA or BSA for 24 hours. TGF-β1 secreted in the
supernatant was measured by standard ELISA. Cultures stimulated with
OVA are represented by black bars; cultures stimulated with BSA are
represented by white bars. Five mice were used in each group in one
experiment. Results are represented as mean ± SD. The experiments
were repeated twice. **p<0.01
Fig. 3 Capacity of anti-TGF-β1 antibody to restore the suppressed
DTH response in vivo by CD8+ T cells from ACAID mice. Regulator
cells consisted of purified CD8+ T cells separated from splenocytes of
ACAID mice. Responder cells were collected from splenocytes of
OVA-primed mice. Group A: positive control; Group B: ACAID
group; Group C: anti-TGF-β1 antibody can partially block the
suppressive effect of CD8+ T cells from ACAID mice; Group D:
isotype control for anti-TGF-β1 antibody. All results are reported as
mean ear swelling ±SD. Each group represents five animals. **p<
0.01;*p<0.05; NS, p>0.05
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stimulation cultured alone may be different from those
cultured with CD4+ T cells. Another study showed that the
neutralizing anti-TGF-β2 antibodies didn’t reverse the
suppressive effect of in vitro-generated ACAID-like CD8+
Tregs [8], while we found that anti-TGF-β1 antibodies
could reverse the suppressive effect of CD8+ Tregs in
ACAID. The discrepancy may be due to the different
blocking antibodies used in the experiments. TGF-β2 has
been considered as a crucial immunomudulatory factor
within the eye. It may contribute to the induction of
ACAID, whereas the TGF-β1 produced by CD8+ T cells
possibly exerts its effect in the expression phase. Our
results are also different from the findings by Kapp et al.
[32]. They found that in vitro TGF-β2-treated APC
activated OT-1 Treg, ACAID-like CD8+ Treg, exert
suppression in a TGF-β-independent manner. The differ-
ence may be due to the origin of CD8+ Tregs. The in vitro
and in vivo models may result in different consequences.
As TGF-β2 is only one of the important immunomodulatory
cytokines existing in AC, the environment in the AC in vivo
is much more complex than the experimental condition used
in vitro. Additionally, we found that the anti-TGF-β1
antibodies could only partially reverse the inhibition of
DTH response by CD8+ Tregs. In our preliminary experi-
ment, three concentrations (200 μg/ml, 100 μg/ml and
50 μg/ml) were used. This study showed a similar result
concerning the first two concentrations, although a lower
effect was found in the concentration of 50 μg/ml (data not
shown). All these results suggest that TGF-β1, is not a sole
factor involved in the inhibition of CD8+ Tregs, and that
other factors, for instance other isoforms of TGF-β or other
cytokines, may also be implicated in this inhibition. A
recent study showed that interferon-γ was required for the
inhibitory activity of these cells [33]. More studies are
needed to clarify the in vivo mechanisms involved in the
suppressive effects mediated by CD8+ Tregs during
ACAID.
In conclusion, our study revealed an inhibitory effect of
CD8+ T cells in a LAT assay, and increased production of
TGF-β1 by these cells. Experiments using anti-TGF-β1
antibodies were able to partially reverse the suppressive
effect of CD8+ Tregs. These results suggest that TGF-β1
may be one of the important cytokines involved in the
suppressive effect mediated by these cells. However, the
form of TGF-β1, soluble, membrane-bound, or both of
them, concerned with this function should be addressed, and
the exact mechanisms involved in the function of efferent
CD8+ Tregs during ACAID needs to be determined.
Acknowledgement This study is supported by Project of Interna-
tional Cooperation in Science and Technology, Guangdong Province
(2004B50301002, 2006A50107001); Key Project of National Natural
Science Foundation (30630064); National Supporting Project of P.R.
China (2007BAI18B10).
Declaration All the listed authors have participated actively in the
study, and have read and approved the submitted manuscript. None of
the authors has any potential financial conflict of interest related to
this manuscript.
References
1. Wilbanks GA, Streilein JW (1990) Characterization of suppressor
cells in anterior chamber-associated immune deviation (ACAID)
induced by soluble antigen. Evidence of two functionally and
phenotypically distinct T-suppressor cell populations. Immunology
71:383–389
2. Letterio JJ, Roberts AB (1998) Regulation of immune responses by
TGF-beta. Annu Rev Immunol 16:137–161, doi:10.1146/annurev.
immunol.16.1.137
3. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006)
Transforming growth factor-beta regulation of immune responses.
Annu Rev Immunol 24:99–146, doi:10.1146/annurev.immunol.
24.021605.090737
4. Zhang X, Izikson L, Liu L, Weiner HL (2001) Activation of CD25
(+)CD4(+) regulatory T cells by oral antigen administration. J
Immunol 167:4245–4253
5. Marie JC, Letterio JJ, Gavin M, Rudensky AY (2005) TGF-beta1
maintains suppressor function and Foxp3 expression in CD4+ CD25+
regulatory T cells. J Exp Med 201:1061–1067, doi:10.1084/
jem.20042276
6. Skelsey ME, Mellon J, Niederkorn JY (2001) Gamma delta T
cells are needed for ocular immune privilege and corneal graft
survival. J Immunol 166:4327–4333
7. Kosiewicz MM, Okamoto S, Miki S, Ksander BR, Shimizu T,
Streilein JW (1994) Imposing deviant immunity on the presensi-
tized state. J Immunol 153:2962–2973
8. Kezuka T, Streilein JW (2000) In vitro generation of regulatory
CD8+ T cells similar to those found in mice with anterior
chamber-associated immune deviation. Invest Ophthalmol Vis Sci
41:1803–1811
9. Jiang L, Yang P, He H, Li B, Lin X, Hou S et al (2007) Increased
expression of Foxp3 in splenic CD8+ Tcells from mice with anterior
chamber-associated immune deviation. Mol Vis 13:968–974
10. Skelsey ME, Mayhew E, Niederkorn JY (2003) Splenic B cells
act as antigen presenting cells for the induction of anterior
chamber-associated immune deviation. Invest Ophthalmol Vis Sci
44:5242–5251, doi:10.1167/iovs.03-0768
11. D’Orazio TJ, Niederkorn JY (1998) A novel role for TGF-beta and IL-
10 in the induction of immune privilege. J Immunol 160:2089–2098
12. Stein-Streilein J, Streilein JW (2002) Anterior chamber associated
immune deviation (ACAID): regulation, biological relevance, and
implications for therapy. Int Rev Immunol 21:123–152,
doi:10.1080/08830180212066
13. Sakaguchi S (2000) Regulatory T cells: key controllers of
immunologic self-tolerance. Cell 101:455–458, doi:10.1016/
S0092-8674(00)80856-9
14. Menoret A, Myers LM, Lee SJ, Mittler RS, Rossi RJ, Vella AT
(2006) TGFbeta protein processing and activity through TCR
triggering of primary CD8+ T regulatory cells. J Immunol
177:6091–6097
15. Myers L, Croft M, Kwon BS, Mittler RS, Vella AT (2005) Peptide-
specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-
beta-based suppression. J Immunol 174:7625–7632
16. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B
et al (2003) Human CD8+ CD25+ thymocytes share phenotypic and
functional features with CD4+ CD25+ regulatory thymocytes. Blood
102:4107–4114, doi:10.1182/blood-2003–04–1320
Graefes Arch Clin Exp Ophthalmol (2009) 247:87–92 91
17. Endharti AT, Rifa IMs, Shi Z, Fukuoka Y, Nakahara Y, Kawamoto Y,
Takeda K, Isobe K, Suzuki H (2005) Cutting edge: CD8+ CD122+
regulatory T cells produce IL-10 to suppress IFN-gamma production
and proliferation of CD8+ T cells. J Immunol 175:7093–7097
18. Gilliet M, Liu YJ (2002) Generation of human CD8 T regulatory
cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp
Med 195:695–704, doi:10.1084/jem.20011603
19. Kang HK, Michaels MA, Berner BR, Datta SK (2005) Very low-
dose tolerance with nucleosomal peptides controls lupus and
induces potent regulatory Tcell subsets. J Immunol 174:3247–3255
20. Maile R, Pop SM, Tisch R, Collins EJ, Cairns BA, Frelinger JA
(2006) Low-avidity CD8lo T cells induced by incomplete antigen
stimulation in vivo regulate naive higher avidity CD8hi T cell
responses to the same antigen. Eur J Immunol 36:397–410,
doi:10.1002/eji.200535064
21. Tang XL, Smith TR, Kumar V (2005) Specific control of
immunity by regulatory CD8 T cells. Cell Mol Immunol 2:11–19
22. Wang Y, Ghali WE, Pingle P, Traboulsi A, Dalal T, O’Rourke J et al
(2003) Splenic T cells from mice receiving intracameral antigen
suppress in-vitro antigen-induced proliferation and interferon-
gamma production by sensitized lymph node cells. Ocul Immunol
Inflamm 11:39–52, doi:10.1076/ocii.11.1.39.15578
23. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al (2003)
Conversion of peripheral CD4+CD25- naive Tcells to CD4+CD25+
regulatory T cells by TGF-beta induction of transcription factor
Foxp3. J Exp Med 198:1875–1886, doi:10.1084/jem.20030152
24. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR,
Neurath MF (2004) Cutting edge: TGF-beta induces a regulatory
phenotype in CD4+ CD25- T cells through Foxp3 induction and
down-regulation of Smad7. J Immunol 172:5149–5153
25. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA (2004)
Natural and induced CD4+ CD25+ cells educate CD4+ CD25-
cells to develop suppressive activity: the role of IL-2, TGF-beta,
and IL-10. J Immunol 172:5213–5221
26. Kezuka T, Streilein JW (2000a) Analysis of in vivo regulatory
properties of T cells activated in vitro by TGFbeta2-treated
antigen presenting cells. Invest Ophthalmol Vis Sci 41:1410–1421
27. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A,
Santos L et al (1994) Oral tolerance: immunologic mechanisms
and treatment of animal and human organ-specific autoimmune
diseases by oral administration of autoantigens. Annu Rev
Immunol 12:809–837, doi:10.1146/annurev.iy.12.040194.004113
28. Hahn BH, Singh RP, La Cava A, Ebling FM (2005) Tolerogenic
treatment of lupus mice with consensus peptide induces Foxp3-
expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell
suppressors. J Immunol 175:7728–7737
29. Nakamura T, Sonoda KH, Faunce DE, Gumperz J, Yamamura T,
Miyake S et al (2003) CD4+ NKT cells, but not conventional CD4+
T cells, are required to generate efferent CD8+ T regulatory cells
following antigen inoculation in an immune-privileged site. J
Immunol 171:1266–1271
30. Ashour HM, Niederkorn JY (2006) Gammadelta T cells promote
anterior chamber-associated immune deviation and immune
privilege through their production of IL-10. J Immunol
177:8331–8337
31. Kosiewicz MM, Alard P, Streilein JW (1998) Alterations in
cytokine production following intraocular injection of soluble
protein antigen: impairment in IFN-gamma and induction of TGF-
beta and IL-4 production. J Immunol 161:5382–5390
32. Kapp JA, Honjo K, Kapp LM, Xu X, Cozier A, Bucy RP (2006)
TCR transgenic CD8+ T cells activated in the presence of
TGFbeta express FoxP3 and mediate linked suppression of
primary immune responses and cardiac allograft rejection. Int
Immunol 18:1549–1562, doi:10.1093/intimm/dxl088
33. Cone RE, Li X, Sharafieh R, O’Rourke J, Vella AT (2007) The
suppression of delayed-type hypersensitivity by CD8+ regulatory
T cells requires interferon-gamma. Immunology 120:112–119,
doi:10.1111/j.1365-2567.2006.02486.x
92 Graefes Arch Clin Exp Ophthalmol (2009) 247:87–92
